On this page
MYL3
myosin light chain 3
MYL3 encodes an essential light chain protein in cardiac muscle that regulates contraction, with pathogenic variants associated with inherited hypertrophic cardiomyopathy. The MYL3 gene produces myosin light chain 3, a regulatory protein critical for normal heart muscle contraction.
MYL3 is located on the short (p) arm of chromosome 3, at band 3p21.31. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Overview
MYL3 provides instructions for producing myosin light chain 3, also known as myosin essential light chain. This protein is predominantly expressed in the ventricular chambers of the heart, where it forms part of the contractile machinery responsible for each heartbeat. The gene is located on chromosome 3 and follows an autosomal dominant inheritance pattern, meaning a single pathogenic variant can be sufficient to cause disease.
Variants in MYL3 are a recognised cause of familial hypertrophic cardiomyopathy, a condition in which the heart muscle becomes abnormally thickened. This can impair the heart's ability to pump blood effectively and may increase the risk of serious cardiac complications. Because early identification allows for surveillance and clinical management strategies that can reduce morbidity and mortality, MYL3 is classified as a medically actionable gene under current international guidelines for genomic screening.
What the gene does
The MYL3 protein functions as an essential component of the cardiac myosin complex, the molecular motor that drives heart muscle contraction. Myosin complexes consist of heavy chains that provide the motor activity and light chains that modulate this activity. MYL3 binds directly to the neck region of the myosin heavy chain, where it plays a structural role in stabilising the lever arm that amplifies small conformational changes in the motor domain into the larger movements required for muscle contraction.
Within each heartbeat cycle, calcium ions trigger a cascade of events that allows myosin heads to bind to actin filaments and pull them inward, shortening the muscle fibre. The essential light chain contributes to the efficiency and coordination of this process by maintaining the proper geometry of the myosin head and lever arm. Experimental evidence suggests that the light chain also influences the rate at which myosin can bind to and release from actin, thereby affecting both the speed and force of contraction.
Because the heart must contract rhythmically and powerfully throughout life, even subtle disruptions to the myosin complex can have significant consequences. Variants that alter the structure or stability of MYL3 may affect how effectively the myosin motor operates, potentially leading to compensatory changes in the heart muscle over time.
Video: Genetics 101
Chromosome location
MYL3 is located on the short arm of chromosome 3 at cytogenetic band 3p21.31. This region of chromosome 3 contains several other genes involved in various cellular processes, but MYL3 is the primary cardiac-specific myosin light chain gene in this neighbourhood. The gene spans a relatively compact genomic region and contains multiple exons that are transcribed and spliced together to produce the mature messenger RNA. The protein-coding sequence is highly conserved across mammalian species, reflecting the critical importance of this protein for cardiac function.
Protein structure
The MYL3 protein comprises 195 amino acids and contains a characteristic arrangement of calcium-binding motifs known as EF-hand domains. The N-terminal region, spanning amino acids 1 to 37, is disordered and lacks a stable three-dimensional structure, which may allow for flexibility in its interactions with the myosin heavy chain. This is followed by EF-hand 1, extending from amino acids 49 to 86, which represents the first structured calcium-binding motif. EF-hand 1 in MYL3 has lost calcium-binding capacity during evolution, while the other EF-hands contribute to structural stability.
The second EF-hand domain, EF-hand 2, occupies amino acids 128 to 163 and works in concert with the first to coordinate calcium ions and stabilise the overall protein fold. The C-terminal portion of the protein contains EF-hand 3, spanning amino acids 163 to 195. These structural elements are crucial for maintaining the protein's conformation and enabling its interaction with the myosin heavy chain. The arrangement of these domains creates a compact, stable structure that can withstand the mechanical forces generated during repeated cycles of muscle contraction.
Key variants
Pathogenic variants in MYL3 are relatively uncommon compared to those in some other cardiomyopathy genes, but they represent an important subset of cases with distinct clinical features. The majority of disease-associated changes are missense variants that alter a single amino acid within the protein sequence, potentially disrupting the structure or binding properties of the essential light chain. Variants have been identified across different regions of the gene, including within the EF-hand domains and in areas critical for interaction with the myosin heavy chain.
Because MYL3 follows autosomal dominant inheritance, individuals who carry one pathogenic variant typically have a 50% chance of passing it to each of their children with each pregnancy. The penetrance and expressivity of these variants can vary, meaning that not all carriers develop disease, and among those who do, the severity and age of onset may differ. Genetic testing for MYL3 variants is most commonly performed in the context of familial hypertrophic cardiomyopathy evaluation or as part of comprehensive cardiomyopathy gene panels.
Sample of pathogenic variants
5 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.281G>A | p.Arg94His | Pathogenic/Likely pathogenic | ★★☆☆ | MYL3-related disorder |
c.445A>G | p.Met149Val | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.447G>T | p.Met149Ile | Likely pathogenic | ★★☆☆ | not provided |
c.81del | p.Glu28fs | Likely pathogenic | ★☆☆☆ | not provided |
c.64G>A | p.Ala22Thr | Likely pathogenic | - | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in MYL3 are primarily associated with hypertrophic cardiomyopathy, a condition characterised by thickening of the heart muscle, particularly affecting the left ventricle. This thickening is not due to increased workload but rather represents an intrinsic abnormality in the cardiac muscle cells themselves. Over time, the thickened muscle can become stiff, reducing the heart's ability to fill properly between beats and potentially leading to symptoms such as shortness of breath, chest pain, palpitations, and in some cases, sudden cardiac events.
The clinical presentation of MYL3-associated cardiomyopathy can vary considerably. Some individuals may remain asymptomatic for many years, while others develop symptoms in childhood or adolescence. Regular cardiac surveillance, including echocardiography and sometimes cardiac MRI, is typically recommended for known carriers to monitor for the development or progression of heart muscle changes. Management strategies may include medications to improve heart function, lifestyle modifications, and in certain circumstances, interventions such as implantable cardioverter-defibrillators to reduce the risk of life-threatening arrhythmias.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic MYL3 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the NHS Genomic Medicine Service, MYL3 is designated with green (high evidence) status on multiple expert-curated gene panels. It appears on the Hypertrophic cardiomyopathy panel (R131 v3.0) and the Paediatric or syndromic cardiomyopathy panel (R135 v3.0), reflecting strong evidence for its role in these conditions and supporting its routine clinical use in diagnostic testing for patients with relevant cardiac presentations. Current panel versions and detailed information are maintained on the NHS PanelApp resource.
The gene's inclusion on these national panels means that NHS genomic laboratories consider MYL3 when performing whole genome or targeted panel sequencing for individuals with suspected inherited cardiomyopathy. This facilitates timely identification of at-risk family members through cascade screening, enabling early monitoring and clinical intervention where appropriate. The actionable nature of findings in this gene also led to its inclusion in the American College of Medical Genetics and Genomics recommendations for reporting secondary findings, a framework that informs genomic medicine practice internationally, including considerations within UK policy discussions.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with hypertrophic cardiomyopathy related to MYL3 variants, research suggests that certain lifestyle modifications may help manage the condition and reduce risks, though these should always be discussed with a cardiologist. General population studies indicate that avoiding high-intensity competitive sports and very strenuous exercise may be prudent for those with established hypertrophic cardiomyopathy, as extreme physical exertion can sometimes trigger arrhythmias in susceptible individuals. Moderate, regular physical activity tailored to individual cardiac status is generally encouraged under medical supervision.
Maintaining a healthy body weight and managing cardiovascular risk factors such as blood pressure and cholesterol may support overall heart health. Some evidence suggests that excessive alcohol consumption should be limited, as alcohol can have direct effects on heart muscle function. Staying well hydrated and avoiding extreme heat or dehydration is often recommended, particularly during physical activity. These are general considerations observed in populations with cardiomyopathy, and personalised advice should always come from a healthcare team familiar with an individual's specific cardiac function and genetic background.
Supplement considerations
There is currently no conclusive evidence that any dietary supplement can prevent or reverse hypertrophic cardiomyopathy in individuals with MYL3 variants. Some individuals with cardiac conditions take supplements such as coenzyme Q10, omega-3 fatty acids, or magnesium based on theoretical benefits for heart muscle metabolism, but rigorous clinical trial data specifically supporting these interventions in genetic cardiomyopathy remain limited.
Before starting any supplement regimen, it is essential to discuss this with a healthcare provider, particularly a cardiologist, as some supplements may interact with cardiac medications or affect heart rhythm. Self-prescribing supplements without medical guidance is not recommended, especially in the context of an inherited heart condition that requires specialist monitoring and management.
Frequently asked questions
What does the MYL3 gene do in the heart?
MYL3 encodes an essential light chain protein that binds to cardiac myosin, the molecular motor responsible for heart muscle contraction. It helps stabilise the structure of the myosin complex and influences how efficiently the heart muscle can contract with each heartbeat.
How is MYL3-related cardiomyopathy inherited?
MYL3 variants that cause cardiomyopathy follow an autosomal dominant pattern of inheritance. This means that inheriting a single pathogenic variant from one parent is sufficient to increase the risk of developing the condition, and each child of a carrier has a 50% chance of inheriting the variant.
If I have a variant in MYL3, will I definitely develop heart problems?
Not necessarily. While pathogenic MYL3 variants significantly increase the risk of hypertrophic cardiomyopathy, penetrance is incomplete, meaning some carriers may never develop clinical signs of the condition. Regular cardiac monitoring is typically recommended to detect changes early if they occur.
Why is MYL3 on the ACMG secondary findings list?
MYL3 is included because it is associated with a medically actionable condition. Identifying pathogenic variants allows for cardiac surveillance and interventions that can reduce the risk of serious complications such as sudden cardiac events, making early detection clinically beneficial even when testing was originally performed for an unrelated reason.
Can lifestyle changes prevent cardiomyopathy in MYL3 variant carriers?
There is no evidence that lifestyle modifications can prevent the development of cardiomyopathy in genetic variant carriers, but certain adjustments may help manage the condition and reduce risks once it develops. Any lifestyle or exercise recommendations should be personalised and discussed with a cardiologist based on individual cardiac status.